Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASTLE BIOSCIENCES, INC.

(CSTL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
41.33(c) 39.52(c) 41.92(c) 41.43(c) 39.94 Last
368 018 295 509 627 468 645 257 312 911 Volume
-0.05% -4.38% +6.07% -1.17% -3.60% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 92,4 M - -
Net income 2021 -36,9 M - -
Net cash position 2021 331 M - -
P/E ratio 2021 -27,3x
Yield 2021 -
Sales 2022 114 M - -
Net income 2022 -38,9 M - -
Net cash position 2022 295 M - -
P/E ratio 2022 -26,5x
Yield 2022 -
Capitalization 1 010 M 1 010 M -
EV / Sales 2021 7,35x
EV / Sales 2022 6,30x
Nbr of Employees 311
Free-Float 90,6%
More Financials
Company
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP)... 
More about the company
Ratings of Castle Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CASTLE BIOSCIENCES, INC.
09:02aCASTLE BIOSCIENCES INC : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
07:01aCastle Biosciences Completes Acquisition of Cernostics
BU
12/03CASTLE BIOSCIENCES INC : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
11/25Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx Der..
AQ
11/24Health Care Stocks Mixed Premarket Wednesday
MT
11/24Castle Biosciences Says Studies Reinforce Clinical Utility of its Gene Expression Profi..
MT
11/24Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® De..
BU
11/24Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its Decisiondx? De..
CI
11/19Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Met..
BU
11/19Castle Biosciences, Inc. announces the publication of a study of patients with stage I-..
CI
11/17Castle Biosciences Named in Inc.'s First-Annual Best-Led Companies
BU
11/15Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
BU
11/10INSIDER SELL : Castle Biosciences
MT
11/10Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and..
BU
11/09SVB Leerink Adjusts Price Target on Castle Biosciences to $75 From $85, Maintains Outpe..
MT
More news
News in other languages on CASTLE BIOSCIENCES, INC.
11/24Les actions du secteur de la santé sont mitigées mercredi avant le marché
11/24Castle Biosciences affirme que des études renforcent l'utilité clinique de ses tests de..
11/10VENTE D'INITIÉS : Castle Biosciences
11/08Earnings Flash (CSTL) CASTLE BIOSCIENCES affiche un chiffre d'affaires de 23,5 millions..
11/08Castle Biosciences, Inc. Relève ses prévisions de revenus pour l'année 2021
More news
Analyst Recommendations on CASTLE BIOSCIENCES, INC.
More recommendations
Chart CASTLE BIOSCIENCES, INC.
Duration : Period :
Castle Biosciences, Inc. Technical Analysis Chart | CSTL | US14843C1053 | MarketScreener
Technical analysis trends CASTLE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 39,94 $
Average target price 87,50 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Derek J. Maetzold President, Chief Executive Officer & Director
Franklin Michael Stokes Chief Financial Officer
Daniel Mark Bradbury Chairman
Robert W. Cook Senior Vice President-Research & Development
Matthew Goldberg Medical Director
Sector and Competitors
1st jan.Capi. (M$)
CASTLE BIOSCIENCES, INC.-41.15%1 048
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.64.99%23 009
BIOMÉRIEUX1.73%15 682
10X GENOMICS, INC.1.90%15 407
DIASORIN S.P.A.3.88%10 914
NATERA, INC.-10.47%8 188